An Emerging Biotech Customer Base Helps Drug Delivery Firms Balance Risks
Executive Summary
When Inhale Therapeutic Systems bought Shearwater, a provider of PEG (polyethylene glycol) technology and development services, it did so to extend its drug delivery capabilities beyond particle-based formulations. But another part of the rationale was to jigger its mix of programs to include both near- and longer-term projects, and to achieve a balance of high- and low-risk projects. As evidenced by its recent spate of deal announcements, the emerging deal-making power of small and mid-sized companies is helping Inhale accomplish those goals.
You may also be interested in...
New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
QUOTED. 9 March 2021. Matthew Trerotola.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Need a specific report? 1000+ reports available
Buy Reports